SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Period	PE Ratio
2016-12-31	N/A
2017-12-31	N/A
2018-12-31	N/A
2019-12-31	N/A
2020-12-31	N/A
2021-12-31	-6.85
2022-12-31	-4.31
2023-12-31	-6.85
2024-12-31	-18.36
2025-12-31	-36.72

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLS	$9.18	+6.99%	10.14M
3
4
5

SELLAS Life Sciences Group Inc. (SLS) PE Ratio

PE Ratio Data

Get SELLAS Life Sciences Group Inc. Data in Excel

More SLS Financial Data